Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Session III: Cross Presentation and Tumor Stroma

Control of tumor immunity by the microenvironment: Overcoming the endothelial barrier

Gunter J. Hämmerling
Gunter J. Hämmerling
German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The clinical success of immunotherapy of tumors is still rather limited. Here we show that the tumor vasculature contributes to this failure. In general, the vasculature of solid tumors displays an aberrant morphology characterized by dilated and fragile vessels, intensive vessel sprouting, and loss of hierarchical architecture. Such an aberrant vasculature is also found in Rip.Tag mice developing autochthonous insulinomas in a multi-step process, therefore resembling the clinical situation. Vaccination against the Tag tumor antigen or transfer of tumor-specific T lymphocytes fails to eliminate the tumors, because the aberrant tumor endothelium forms a barrier against infiltration by tumor-specific lymphocytes. However, induction of an inflammatory environment in the tumor, e.g. by irradiation or immunostimulatory CpG oligonucleotides, will result in activation of the endothelia and in efficient infiltration of effector cells into the tumor tissue and tumor eradication.

Gene expression profiling identified RGS5 (regulator of G protein signalling 5) as a master gene that seems to be involved in the barrier function as suggested by its selective overexpression in pericytes of the tumor vasculature. Interestingly, tumors developing in RGS5 knockout mice display a normalized tumor vasculature. Moreover, this normalized vasculature permits strong T cell infiltration resulting in tumor eradication.

In conclusion, we suggest that for successful immunotherapy of cancer vaccination or adoptive T cell transfer should be combined with an anti-angiogenic therapy resulting in modulation or normalization of the tumor vasculature, and, thereby, to enhanced T cell infiltration. These observations open the way for novel therapeutic interventions.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Gunter J. Hämmerling
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 2)
January 2008
Volume 8, Issue Suppl 2
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Control of tumor immunity by the microenvironment: Overcoming the endothelial barrier
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Control of tumor immunity by the microenvironment: Overcoming the endothelial barrier
Gunter J. Hämmerling
Cancer Immun January 1 2008 (8) (Suppl 2) 12;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Control of tumor immunity by the microenvironment: Overcoming the endothelial barrier
Gunter J. Hämmerling
Cancer Immun January 1 2008 (8) (Suppl 2) 12;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Molecular nature of the antigenic entity transferred from antigen donor cell to antigen presenting cells during cross presentation
  • Antigen presentation and the T-cell response
  • Open sesame: The endothelin (B) receptor mediates the tumor endothelial barrier to T-cell homing
Show more Session III: Cross Presentation and Tumor Stroma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement